Results 71 to 80 of about 106,604,922 (252)
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Dagstuhl Reports, Volume 3, Issue 09, September 2013, Complete Issue
Dagstuhl Reports, Volume 3, Issue 09, September 2013, Complete ...
core +1 more source
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens +6 more
wiley +1 more source
Volume 9, No.3, September 2010 ISSN 1412 ...
September 2010 ISSN 1412-2782, Volume 9, No.3,
core +1 more source
Dagstuhl Reports, Volume 10, Issue 3, March 2020, Complete Issue
Dagstuhl Reports, Volume 10, Issue 3, March 2020, Complete ...
core +1 more source
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur +11 more
wiley +1 more source
Volume 3, Issue 3: Spring 2024
Frontmatter for JPSS 3(3)
Shouping Hu
doaj

